Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
237 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Duchenne Muscular Dystrophy - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Duchenne Muscular Dystrophy - Pipeline Review, H1 2015', provides an overview of the Duchenne Muscular Dystrophy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Duchenne Muscular Dystrophy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Duchenne Muscular Dystrophy Overview 9 Therapeutics Development 10 Pipeline Products for Duchenne Muscular Dystrophy - Overview 10 Pipeline Products for Duchenne Muscular Dystrophy - Comparative Analysis 11 Duchenne Muscular Dystrophy - Therapeutics under Development by Companies 12 Duchenne Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes 16 Duchenne Muscular Dystrophy - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Duchenne Muscular Dystrophy - Products under Development by Companies 20 Duchenne Muscular Dystrophy - Products under Investigation by Universities/Institutes 25 Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development 26 Acceleron Pharma, Inc. 26 Asklepios BioPharmaceutical, Inc. 27 Bristol-Myers Squibb Company 28 Catabasis Pharmaceuticals, Inc. 29 Daiichi Sankyo Company, Limited 30 Eli Lilly and Company 31 EryDel SPA 32 Fate Therapeutics, Inc. 33 Galapagos NV 34 Genethon 35 Idera Pharmaceuticals, Inc. 36 Italfarmaco S.p.A. 37 Marathon Pharmaceuticals, LLC 38 Marina Biotech, Inc. 39 miRagen Therapeutics, Inc. 40 NicOx S.A. 41 Nippon Shinyaku Co., Ltd. 42 nLife Therapeutics, S.L. 43 Nobelpharma Co., Ltd. 44 Pfizer Inc. 45 Prosensa Therapeutics B.V. 46 Prothelia, Inc. 47 PTC Therapeutics, Inc. 48 Reata Pharmaceuticals, Inc. 49 Retrophin Inc. 50 ReveraGen BioPharma, Inc. 51 Sanofi 52 Santhera Pharmaceuticals Holding AG 53 Sarepta Therapeutics, Inc. 54 Shenzhen Beike Biotechnology Co., Ltd. 55 Shire Plc 56 Summit Corporation plc 57 Taiho Pharmaceutical Co., Ltd. 58 Zambon Company S.p.A. 59 Duchenne Muscular Dystrophy - Therapeutics Assessment 60 Assessment by Monotherapy Products 60 Assessment by Combination Products 61 Assessment by Target 62 Assessment by Mechanism of Action 64 Assessment by Route of Administration 66 Assessment by Molecule Type 68 Drug Profiles 70 AAV1-FS-344 - Drug Profile 70 ACE-083 - Drug Profile 71 Antisense Oligonucleotide for Duchenne Muscular Dystrophy - Drug Profile 72 Antisense Oligonucleotide to Activate Dystrophin for Duchene Muscular Dystrophy - Drug Profile 73 Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 74 Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 75 arbekacin - Drug Profile 76 ARM-210 - Drug Profile 77 AT-300 - Drug Profile 78 ataluren - Drug Profile 80 Biostrophin - Drug Profile 83 BMS-986089 - Drug Profile 84 CAT-1004 - Drug Profile 85 CAT-1040 - Drug Profile 87 CAT-1041 - Drug Profile 88 deflazacort - Drug Profile 89 dexamethasone sodium phosphate - Drug Profile 90 drisapersen - Drug Profile 92 Drugs for Duchenne Muscular Dystrophy - Drug Profile 94 DT-200 - Drug Profile 95 eteplirsen - Drug Profile 97 Gene Therapy for Duchenne Muscular Dystrophy - Drug Profile 100 Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies - Drug Profile 101 Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 102 givinostat - Drug Profile 103 halofuginone hydrobromide - Drug Profile 105 idebenone - Drug Profile 108 IMO-8400 - Drug Profile 110 MG-53 - Drug Profile 112 MGN-8107 - Drug Profile 114 naproxcinod - Drug Profile 115 NBD Peptide - Drug Profile 117 NS-065 - Drug Profile 119 NU-21101 + NU-21502 - Drug Profile 120 Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile 121 OSX-200 - Drug Profile 122 Peptides for Duchenne Muscular Dystrophy and Cardiac Disease - Drug Profile 123 PF-06252616 - Drug Profile 124 poloxamer - Drug Profile 125 PRO-044 - Drug Profile 127 PRO-045 - Drug Profile 129 PRO-052 - Drug Profile 131 PRO-053 - Drug Profile 133 PRO-055 - Drug Profile 135 PROSPECT - Drug Profile 136 PRT-01 - Drug Profile 137 PRT-20 - Drug Profile 138 PRT-300 - Drug Profile 139 PRT-400 - Drug Profile 140 PRT-500 - Drug Profile 141 RE-001 - Drug Profile 142 Recombinant Protein for Muscular Dystrophy - Drug Profile 143 Recombinant Proteins for Duchenne Muscular Dystrophy - Drug Profile 144 RNAi Oligonucleotides for Duchenne Muscular Dystrophy - Drug Profile 145 RTC-13 - Drug Profile 146 SHP-619 - Drug Profile 148 Small Molecule for Duchenne Muscular Dystrophy - Drug Profile 149 Small Molecule for Muscular Dystrophy and Other Muscle Disorders - Drug Profile 150 Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 152 Small Molecule to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile 153 Small Molecules to Activate Nrf2 for Duchenne Muscular Dystrophy - Drug Profile 154 Small Molecules to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile 155 Small Molecules to Target Utrophin for Duchenne Muscular Dystrophy - Drug Profile 156 SMTC-1100 - Drug Profile 157 SRP-4008 - Drug Profile 159 SRP-4044 - Drug Profile 160 SRP-4045 - Drug Profile 161 SRP-4050 - Drug Profile 162 SRP-4052 - Drug Profile 163 SRP-4053 - Drug Profile 164 SRP-4055 - Drug Profile 165 Stem Cell Therapy for Duchenne Muscular Dystrophy - Drug Profile 166 Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 167 tadalafil - Drug Profile 169 TAS-205 - Drug Profile 171 TVN-102 - Drug Profile 172 TXA-127 - Drug Profile 173 VBP-15 - Drug Profile 175 ZP-049 - Drug Profile 177 Duchenne Muscular Dystrophy - Recent Pipeline Updates 178 Duchenne Muscular Dystrophy - Dormant Projects 220 Duchenne Muscular Dystrophy - Discontinued Products 222 Duchenne Muscular Dystrophy - Product Development Milestones 223 Featured News & Press Releases 223 Appendix 230 Methodology 230 Coverage 230 Secondary Research 230 Primary Research 230 Expert Panel Validation 230 Contact Us 230 Disclaimer 231
List of Tables Number of Products under Development for Duchenne Muscular Dystrophy, H1 2015 16 Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H1 2015 17 Number of Products under Development by Companies, H1 2015 19 Number of Products under Development by Companies, H1 2015 (Contd..1) 20 Number of Products under Development by Companies, H1 2015 (Contd..2) 21 Number of Products under Investigation by Universities/Institutes, H1 2015 22 Comparative Analysis by Late Stage Development, H1 2015 23 Comparative Analysis by Clinical Stage Development, H1 2015 24 Comparative Analysis by Early Stage Development, H1 2015 25 Products under Development by Companies, H1 2015 26 Products under Development by Companies, H1 2015 (Contd..1) 27 Products under Development by Companies, H1 2015 (Contd..2) 28 Products under Development by Companies, H1 2015 (Contd..3) 29 Products under Development by Companies, H1 2015 (Contd..4) 30 Products under Investigation by Universities/Institutes, H1 2015 31 Duchenne Muscular Dystrophy - Pipeline by Acceleron Pharma, Inc., H1 2015 32 Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2015 33 Duchenne Muscular Dystrophy - Pipeline by Bristol-Myers Squibb Company, H1 2015 34 Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015 35 Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 36 Duchenne Muscular Dystrophy - Pipeline by Eli Lilly and Company, H1 2015 37 Duchenne Muscular Dystrophy - Pipeline by EryDel SPA, H1 2015 38 Duchenne Muscular Dystrophy - Pipeline by Fate Therapeutics, Inc., H1 2015 39 Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H1 2015 40 Duchenne Muscular Dystrophy - Pipeline by Genethon, H1 2015 41 Duchenne Muscular Dystrophy - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 42 Duchenne Muscular Dystrophy - Pipeline by Italfarmaco S.p.A., H1 2015 43 Duchenne Muscular Dystrophy - Pipeline by Marathon Pharmaceuticals, LLC, H1 2015 44 Duchenne Muscular Dystrophy - Pipeline by Marina Biotech, Inc., H1 2015 45 Duchenne Muscular Dystrophy - Pipeline by miRagen Therapeutics, Inc., H1 2015 46 Duchenne Muscular Dystrophy - Pipeline by NicOx S.A., H1 2015 47 Duchenne Muscular Dystrophy - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 48 Duchenne Muscular Dystrophy - Pipeline by nLife Therapeutics, S.L., H1 2015 49 Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co., Ltd., H1 2015 50 Duchenne Muscular Dystrophy - Pipeline by Pfizer Inc., H1 2015 51 Duchenne Muscular Dystrophy - Pipeline by Prosensa Therapeutics B.V., H1 2015 52 Duchenne Muscular Dystrophy - Pipeline by Prothelia, Inc., H1 2015 53 Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H1 2015 54 Duchenne Muscular Dystrophy - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 55 Duchenne Muscular Dystrophy - Pipeline by Retrophin Inc., H1 2015 56 Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H1 2015 57 Duchenne Muscular Dystrophy - Pipeline by Sanofi, H1 2015 58 Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2015 59 Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H1 2015 60 Duchenne Muscular Dystrophy - Pipeline by Shenzhen Beike Biotechnology Co., Ltd., H1 2015 61 Duchenne Muscular Dystrophy - Pipeline by Shire Plc, H1 2015 62 Duchenne Muscular Dystrophy - Pipeline by Summit Corporation plc, H1 2015 63 Duchenne Muscular Dystrophy - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 64 Duchenne Muscular Dystrophy - Pipeline by Zambon Company S.p.A., H1 2015 65 Assessment by Monotherapy Products, H1 2015 66 Assessment by Combination Products, H1 2015 67 Number of Products by Stage and Target, H1 2015 69 Number of Products by Stage and Mechanism of Action, H1 2015 71 Number of Products by Stage and Route of Administration, H1 2015 73 Number of Products by Stage and Molecule Type, H1 2015 75 Duchenne Muscular Dystrophy Therapeutics - Recent Pipeline Updates, H1 2015 184 Duchenne Muscular Dystrophy - Dormant Projects, H1 2015 226 Duchenne Muscular Dystrophy - Dormant Projects (Contd..1), H1 2015 227 Duchenne Muscular Dystrophy - Discontinued Products, H1 2015 228
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
